Third Open Scientific EIP Symposium; "Immunogenicity of Biopharmaceuticals"

Start:
8 December 2010
Location:
Domenican cloister (13-18th century) Het Pand, Gent, Belgium

Organized by the European Immunogenicity Platform (EIP), a central meeting place for European biopharmaceutical companies and scientific experts active in the field of immunogenicity.

Talk and discuss with the experts in immunogenicity! 

The meeting format – with plenary lectures and interactive working groups with no more than 40 people – will give everyone the opportunity to meet the experts and discuss novel technologies.

The conference program will be updated on a daily basis on the website and includes

  • A renown speaker-panel, including Irun Cohen (Weizmann Institute, IS), John Carpenter (U.C. Denver, USA), Robin Thorpe NISCB, UK), Filip Baert (HHR, BE), Jean-Marie Saint-Remy (K.U.Leuven, BE), David Wraith (Bristol University, UK)
  • A networking event in the Gent museum for contemporary art SMAK (Wed. December 8th)
     

Venue
The symposium is held in the historic center of Gent, in the refurbished Domenican cloister (13-18th century) Het Pand, Onderbergen 1, 9000 Gent,

Registration, fees and abstract submission:
The conference fee is 595,- Euro, including the conference, refreshments and the social event. Registration can be done online on http://www.e-i-p.eu. A confirmation letter (with invoice) will be sent after registration.
Registration and abstract submission are possible until December 1st 2010, with a maximum of 120 participants.

Hotel accommodation:
Hotel accommodation is not included in the course fee. We have made blocked bookings at 3 nearby hotels, the Marriot, Novotel and Ibis hotels, and have made 50 rooms available for our participants.

Please make your own reservation at these hotels, which should be requested timely. Availability cannot be guaranteed beyond October 1st 2010. Reservation forms for these hotels and more information are available on the EIP website.

Congress President:
Huub Schellekens, Department of Pharmaceutical Sciences, Utrecht University, Netherlands

Organization Committee:
Sebastian Spindeldreher, Novartis, Switzerland
Arno Kromminga, IPM Biotech, Germany
Christian Ross, Novo Nordisk, Switzerland
Birgit Reipert, Baxter, Austria
Philippe Stas, Lonza, Belgium
Wim Jiskoot, Leiden University, Netherlands